Voyager Therapeutics Inc to Discuss Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson's Disease - Conference Ca
Conference Call Voyager Therapeutics Inc
Voyager Therapeutics Inc Conference call will be held on Mar 9, 2018. During the earnings conference call's session Voyager Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Voyager Therapeutics Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system, or CNS. We focus on CNS diseases where we believe that an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. We have created a product engine that enables us to engineer, optimize, manufacture and deliver our AAV-based therapies that have the potential to provide durable efficacy following a single administration directly to the CNS. Our product engine has rapidly generated programs for five CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis, or a form of the disease caused by a single gene mutation; Friedreich's ataxia; Huntington's disease; and spinal muscular atrophy.Read more Conference Call